# Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

> **NCT02711137** · PHASE1,PHASE2 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 137 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** INCB057643
- **DRUG:** Gemcitabine
- **DRUG:** Paclitaxel
- **DRUG:** Rucaparib
- **DRUG:** Abiraterone
- **DRUG:** Ruxolitinib
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT02711137
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05-18
- **Primary completion:** 2019-02-13
- **Final completion:** 2019-02-13
- **Target enrollment:** 137 (ACTUAL)
- **Why stopped:** Study terminated due to safety issues.
- **Last updated:** 2025-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02711137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02711137, "Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02711137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*